Stifel Downgrades Silk Road Medical to Hold, Raises Price Target to $27.5
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Hold while raising the price target from $23 to $27.5.
July 17, 2024 | 9:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Rick Wise downgraded Silk Road Medical from Buy to Hold, but raised the price target from $23 to $27.5.
The downgrade from Buy to Hold suggests a neutral stance on the stock, which could lead to a short-term stabilization or slight decline in the stock price. However, the raised price target indicates some positive outlook, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100